Michelle Monje, MD, PhD
Michelle Monje, MD, PhD, scientific director of the Stanford Center for Childhood Brain Tumors, is a professor of neurology and neurological sciences at Stanford University and the Lucile Packard Children’s hospital and an endowed Stanford Medicine Faculty Scholar.
Dr. Monje is a neuroscientist and practicing pediatric neuro-oncologist whose research program focuses at the intersection of neuroscience and brain cancer biology. Her work has focused on neuron-glial interactions in health and oncological disease. Her lab demonstrated that neuronal activity regulates healthy glial precursor cell proliferation, new oligodendrocyte generation and adaptive myelination (Gibson et al., 2014 Science) and that this plasticity of myelin contributes to healthy cognitive function (Geraghty et al, 2019 Neuron; Steadman et al., 2019 Neuron). She discovered that neuronal activity similarly promotes the proliferation of malignant glioma cells, driving glioma growth through both paracrine factors and through electrophysiologically functional neuron-to-glioma synapses (Venkatesh et al., 2015, Cell; Venkatesh et al., 2017 Nature; Venkatesh et al., 2019 Nature).
In addition to these studies of mature neurons in the glioma microenvironment, her research program also study the influences of neural precursor cells on malignant glioma (Qin et al., 2017, Cell). Microglial interactions with neurons and neural precursor cells and microglial-mediated disruption of neuroplasticity mechanisms underlying cognitive function following cancer therapies is another area of deep focus (Monje et al, 2002, Nature Medicine, Monje et al, 2003, Science, Monje et al, 2007, Annals of Neurology, Gibson et al., 2019 Cell; Geraghty et al, 2019 Neuron). Together with these basic studies, her research program executes preclinical studies of novel therapeutics for pediatric high-grade gliomas (Grasso et al, 2015, Nature Medicine; Nagaraja et al, 2017, Cancer Cell; Mount et al, 2018 Nature Medicine; Lin et al, 2019 Science Translational Medicine) and cancer therapy-related cognitive impairment (Gibson et al., 2019 Cell; Geraghty et al, 2019 Neuron) in order to translate new therapies to the clinic. She has led several of her discoveries to national, cooperative clinical trials for children with brain tumors.
Dr. Monje is recognized as an international leader in the pathophysiology of childhood gliomas, especially diffuse midline gliomas and diffuse intrinsic pontine glioma (DIPG). Her work has been recognized by numerous honors, including a Presidential Early Career Award for Science and Engineering (PECASE), an NIH Director’s Pioneer Award (DP1), the Sidney Carter Award in Child Neurology and the Jerome Posner Neuro-Oncology Investigator Award, from the American Academy of Neurology. She is on the editorial advisory board for multiple academic journals, including Cancer Cell, Neuron and Neuro-Oncology.
Dr. Monje received her M.D. and Ph.D. in Neuroscience from Stanford University and then completed her residency training in neurology at the Massachusetts General Hospital/Brigham and Women’s Hospital/Harvard Medical School Partners program. She returned to Stanford for a clinical fellowship in pediatric neuro-oncology and a post-doctoral fellowship with Dr. Philip Beachy.
Awards and Recognitions
2021 The MacArthur Foundation Fellowship
2021 Appointment as a Howard Hughes Medical Institute Investigator
2021 Elected to the National Academy of Medicine
2020 F.E. Bennett Memorial Lectureship Award, American Neurological Association
2020 Stanford Medicine Endowed Faculty Scholar
2019 Sidney Carter Award in Child Neurology, American Academy of Neurology
2019 Presidential Early Career Award in Science and Engineering (PECASE)
2018 NIH Director’s Pioneer Award
2017 The Jerome Posner Neuro-Oncology Investigator Award, American Academy of Neurology
2017 The Innovative Researcher Award, DIPG Collaborative
Recent and Notable Publications
GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas
Majzner, R.G., Ramakrishna, S., Yeom, K.W. et al. GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas. Nature 603, 934–941 (2022). https://doi.org/10.1038/s41586-022-04489-4
Neuronal activity promotes glioma growth through neuroligin-3 secretion
Venkatesh HS, Johung T, Caretti V, Noll A, Tang Y, Nagaraja S, Gibson EM, Mount CW, Pollepalli J, Mitra SS, Woo PJ, Malenka RM, Vogel H, Bredel M, Mallick P, Monje M (2015) Neuronal activity promotes glioma growth through neuroligin-3 secretion, Cell, 161(4):803-16. PMCID: PMC4447122
Targeting neuronal activity-regulated neuroligin-3 dependency for high-grade glioma
Venkatesh HS, Tam LT, Woo PJ, Nagaraja S, Gillespe SM, Lennon J, Ni J, Duveau DY, Morris PJ, Zhao JJ, Thomas CJ, Monje M (2017) Targeting neuronal activity-regulated neuroligin-3 dependency for high-grade glioma, Nature 549: 533-537. PMCID: PMC5891832
Electrical and synaptic integration of glioma into neural circuits
Venkatesh HS, Morishita W, Geraghty AC, Silverbush D, Gillespie SM, Arzt M, Tam LT, Espenel C, Ponnuswami A, Ni L, Woo PJ, Taylor KR, Agarwal A, Regev A, Brang D, Vogel H, Hervey-Jumper S, Bergles DE, Suvà ML, Malenka RC and Monje M (2019) Electrical and synaptic integration of glioma into neural circuits Nature 573:539-545 NIHMS 1537449
Functionally defined therapeutic targets in diffuse intrinsic pontine glioma.
Grasso CS, Y. Tang, N. Truffaux…E. H. Raabe, E. Hulleman, P. T. Spellman, X. N. Li, C. Keller, R. Pal, J. Grill, Monje M (2015) Functionally defined therapeutic targets in diffuse intrinsic pontine glioma. Nature Med, 21(6): 555- 559. PMCID: PMC4862411
Transcriptional dependencies in diffuse intrinsic pontine glioma
Nagaraja S, Vitanza N, Woo PJ, Taylor KR, Liu F, Zhang L, Li M, Meng W, Ponnuswami A, Sun W, Ma J, Hulleman E, Swigut T, Wysocka J, Tang Y, Monje M (2017) Transcriptional dependencies in diffuse intrinsic pontine glioma, Cancer Cell, 31(5):635-652. PMCID: PMC5462626
Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M(+) diffuse midline gliomas
Mount CW, Majzner RG…Vogel H, Monje M* and Mackall CL* (2018) Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M(+) diffuse midline gliomas. Nature Medicine 24(5):572-579. PMCID PMC6214371
Therapeutic opportunities for diffuse midline glioma identified from high-throughput combination drug screening
Lin G.L., Wilson K.M…Warren K.E.*, Thomas C.J.*, Monje M* (2019) Therapeutic opportunities for diffuse midline glioma identified from high-throughput combination drug screening. Science Translational Medicine, 11(519):eaaw0064